Overview

Effects of Rosuvastatin on Aortic Stenosis Progression

Status:
Completed
Trial end date:
2008-09-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the effects of rosuvastatin compared to usual care in patients diagnosed with aortic valvular stenosis. Patients must have a diagnosis of mild to moderate aortic stenosis (AS) and no clinical indication for the use of cholesterol lowering agents. A multi-centre, randomized, double-blind, placebo-controlled study, with a two year recruitment period, and a treatment duration of a minimum of 3 years from the time of the last patient randomized to a maximum of 5 years.
Phase:
Phase 3
Details
Lead Sponsor:
AstraZeneca
Collaborator:
Ottawa Heart Institute Research Corporation
Treatments:
Rosuvastatin Calcium